Response rates of patients with cutaneous melanoma to the first ICI therapy were compared between the groups of HLA-A*02:01 positive patients (n = 14) and HLA-A*02:01 negative patients (n = 25). This evidence concerns the gene HLA-A and cutaneous melanoma.